Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byAmgen
Price$315M
Date4/2012
TermsCash

General Information

Offices

South San Francisco, USA
270 Littlefield Avenue
South San Francisco, CA, 94080
USA

People

Founder / CSO / Scientific Consultant / Chairperson, Scientific Advisory Board Director
Board of Directors
Scientific Advisory Boards

Funding

Tags

KAI Pharmaceuticals

KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.

Recent Milestones

Videos

Screenshots

KAI Pharmaceuticals screenshot
Above: KAI Pharmaceuticals
Uploaded: 4/20/10

Sources

  1. UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout (fiercebiotech.com) [edit]
  2. KAI Pharmaceuticals Completes $35 Million Series B Financing (kaipharmaceuticals.com) [edit]
Edit This Page
Last Edited 4/8/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy